DOP2015000089A - Composición de difenidol de liberación prolongada - Google Patents

Composición de difenidol de liberación prolongada

Info

Publication number
DOP2015000089A
DOP2015000089A DO2015000089A DO2015000089A DOP2015000089A DO P2015000089 A DOP2015000089 A DO P2015000089A DO 2015000089 A DO2015000089 A DO 2015000089A DO 2015000089 A DO2015000089 A DO 2015000089A DO P2015000089 A DOP2015000089 A DO P2015000089A
Authority
DO
Dominican Republic
Prior art keywords
agents
composition
difenidol
prolonged release
release
Prior art date
Application number
DO2015000089A
Other languages
English (en)
Inventor
Guadalupe Resendiz-Hernandez
Original Assignee
Invekra S A P I De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invekra S A P I De C V filed Critical Invekra S A P I De C V
Publication of DOP2015000089A publication Critical patent/DOP2015000089A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe una composición farmacéutica de difenidol de liberación prolongada que comprende: a) de 15 a 50% de clorhidrato de difenidol; b) de 0.1 a 20% de uno o más agentes aglutinantes; c) de 5 a 90% de uno o más agentes diluentes; d) de 5 a 50% de uno o más agentes modificadores de la liberación; e) de 0.25 a 10% de uno o más agentes lubricantes; y f) 0.1 a 10% de agentes deslizantes. De manera preferida, esta composición farmacéutica se administra por vía oral y se encuentra en forma de tableta.
DO2015000089A 2013-01-16 2015-04-17 Composición de difenidol de liberación prolongada DOP2015000089A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2013000662A MX356789B (es) 2013-01-16 2013-01-16 Composición de difenidol de liberación prolongada.

Publications (1)

Publication Number Publication Date
DOP2015000089A true DOP2015000089A (es) 2015-05-15

Family

ID=51209070

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2015000089A DOP2015000089A (es) 2013-01-16 2015-04-17 Composición de difenidol de liberación prolongada

Country Status (11)

Country Link
US (1) US10188610B2 (es)
BR (1) BR112015011351B1 (es)
CA (1) CA2889283C (es)
CL (1) CL2015001128A1 (es)
CR (1) CR20150275A (es)
DO (1) DOP2015000089A (es)
EC (1) ECSP15030460A (es)
GT (1) GT201500038A (es)
MX (1) MX356789B (es)
PE (1) PE20150888A1 (es)
WO (1) WO2014111799A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108283625A (zh) * 2018-04-26 2018-07-17 江苏四环生物制药有限公司 一种盐酸地芬尼多片的制备方法
CN110638775A (zh) * 2019-10-25 2020-01-03 仁和堂药业有限公司 一种盐酸地芬尼多片剂及其应用
CN110638776A (zh) * 2019-10-25 2020-01-03 仁和堂药业有限公司 盐酸地芬尼多片的制备工艺
CN110934842A (zh) * 2019-11-26 2020-03-31 卓和药业集团有限公司 盐酸地芬尼多片的制备方法
CN112315925A (zh) * 2020-11-16 2021-02-05 仁和堂药业有限公司 盐酸米安色林片及其制备工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6143108A (ja) * 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd 医薬品製剤及びその製造法
WO1991006281A1 (en) * 1989-10-26 1991-05-16 Nippon Shinyaku Co., Ltd. Gastric preparation
CN1935140A (zh) 2005-09-19 2007-03-28 长沙佰川医药科技开发有限责任公司 复方盐酸地芬尼多分散片剂及其制备方法
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
WO2008146178A2 (en) * 2007-05-30 2008-12-04 Wockhardt Research Centre A novel tablet dosage form
KR101051630B1 (ko) * 2008-10-02 2011-07-26 한국유나이티드제약 주식회사 용출률과 복용편의성이 향상된 트리메부틴 서방정
NZ594648A (en) * 2009-03-03 2013-12-20 Xenoport Inc Sustained release oral dosage forms of an r-baclofen prodrug

Also Published As

Publication number Publication date
WO2014111799A1 (es) 2014-07-24
MX2013000662A (es) 2014-07-16
PE20150888A1 (es) 2015-06-08
BR112015011351A2 (pt) 2017-07-11
US20150352051A1 (en) 2015-12-10
CL2015001128A1 (es) 2015-10-09
CR20150275A (es) 2015-07-08
US10188610B2 (en) 2019-01-29
CA2889283A1 (en) 2014-07-24
MX356789B (es) 2018-06-12
BR112015011351B1 (pt) 2021-11-23
ECSP15030460A (es) 2017-08-31
CA2889283C (en) 2020-12-29
GT201500038A (es) 2019-08-02

Similar Documents

Publication Publication Date Title
CL2016001547A1 (es) Composiciones para el cuidado oral
CY1120529T1 (el) Προφαρμακα φουμαρικων αλατων και η χρηση τους στην αγωγη ποικιλων νοσων
CL2016001544A1 (es) Composición dentífrica que comprende óxido de zinc y citrato de zinc
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
DOP2015000183A (es) Formulaciones farmacéuticas resistentes a la manipulación indebida
GT201300309A (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2- pirimidinil]-amino]-n-[5-(4-metil -1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
DOP2015000089A (es) Composición de difenidol de liberación prolongada
IT1398930B1 (it) Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi.
CL2012003729A1 (es) Composicion farmaceutica oral que comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, uno o mas rellenos, un desintegrante y un lubricante; proceso de preparacion de la composicion.
CL2015002755A1 (es) Composiciones antibióticas de ceftolozano.
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
PE20142284A1 (es) Procedimiento de fabricacion de una forma de dosificacion farmaceutica que comprende nifedipina y candesartan cilexetilo
AR098888A1 (es) Composición para el cuidado oral
BR122020011180B8 (pt) formulações injetáveis de compostos de tetraciclina
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
CL2015001940A1 (es) Formulación que comprende un compuesto de benzotiazolona.
BR112015028025A2 (pt) composição farmacêutica adaptada para administração oral e regime de tratamento para o controle de insuficiência adrenal
PE20120515A1 (es) Formulaciones de deferiprona
PE20151432A1 (es) Formulaciones de lorazepam de liberacion sostenida
ES2475942B1 (es) Composición farmacéutica de citrato de sildenafilo en forma de solución acuosa
CL2016000542A1 (es) Composición que comprende hidroxipropil quitosano junto con excipientes y/o adyuvantes farmacéuticamente aceptables; útil en el tratamiento de la onicomicosis.
AR100153A1 (es) Medicamento